

**Table S2.** Association of participant characteristics and plasma biomarker factors with DSP signs and symptoms (n = 132).

	DSP*		Presence of any DSP Symptoms		DNP		Presence of Paresthesia (Tingling)		Loss of Sensation	
	OR (95%CI)	p	OR (95%CI)	p	OR (95%CI)	p	OR (95%CI)	p	OR (95%CI)	
Univariable regression model										
age	1.11 (1.05-1.17)	<0.001	1.04 (1.01-1.07)	0.02	1.04 (1.00-1.08)	0.05	1.03 (0.99-1.06)	0.08	1.01 (0.97-1.04)	0.80
Gender (male)	0.27 (0.06-1.27)	0.1	0.56 (0.23-1.37)	0.20	0.42 (0.11-1.56)	0.20	0.41 (0.14-1.17)	0.09	0.38 (0.11-1.42)	0.15
Ethnicity (Hispanic)	1.23 (0.19-8.00)	0.83	0.34 (0.07-1.74)	0.20	0.58 (0.06-5.99)	0.65	0.56 (0.10-3.07)	0.51	0.70 (0.12-3.94)	0.68
Height	1.12 (0.98-1.29)	0.09	1.05 (0.95-1.15)	0.35	1.05 (0.93-1.18)	0.46	1.13 (1.01-1.27)	0.03	1.08 (0.96-1.22)	0.22
Diabetes Mellitus	0.75 (0.08-6.75)	0.81	2.37 (0.50-11.21)	0.27	3.17 (0.56-17.91)	0.19	2.37 (0.50-11.21)	0.55	<0.001 (<0.001- )	0.99
Metabolic Syndrome	0.61 (0.21-1.82)	0.38	2.76 (1.23-6.19)	0.01	2.53 (0.88-7.33)	0.08	2.03 (0.85-4.84)	0.11	1.67 (0.60-4.65)	0.33
Framingham CVD risk score	1.08 (1.03-1.13)	<0.001	1.06 (1.02-1.10)	0.003	1.07 (1.03-1.12)	0.002	1.05 (1.01-1.09)	0.02	1.03 (0.98-1.07)	0.25
Lifetime alcohol use disorder	1.29 (0.42-3.95)	0.66	1.28 (0.57-2.88)	0.54	1.24 (0.43-3.56)	0.69	1.88 (0.76-4.66)	0.17	1.87 (0.65-5.41)	0.25
Lifetime methamphetamine use disorder	1.70 (0.33-8.69)	0.52	0.81 (0.36-1.82)	0.61	1.49 (0.51-4.28)	0.46	0.68 (0.28-1.65)	0.39	0.97 (0.35-2.71)	0.96
Lifetime opioid use disorder	<0.001 (<0.001-)	0.99	0.63 (0.13-3.08)	0.57	0.67 (0.08-5.59)	0.71	0.89 (0.18-4.40)	0.88	0.62 (0.07-5.17)	0.66
HIV seropositivity	3.32 (1.00-11.03)	0.049	4.81 (1.97-11.73)	<0.001	1.07 (1.03-1.12)	0.01	6.15 (2.15-17.57)	<0.001	10.10 (2.21-46.23)	0.003
Factor 1	1.66 (0.90-3.09)	0.10	1.59 (1.01-2.53)	0.05	1.77 (0.96-3.24)	0.06	1.52 (0.92-2.50)	0.1	1.16 (0.65-)	0.62
Factor 2	2.01 (1.05-3.64)	0.02	2.03 (1.26-3.25)	0.003	1.82 (1.03-3.23)	0.04	2.15 (1.29-3.57)	0.003	2.54 (1.39-4.63)	0.002
Factor 3	1.70 (0.91-3.19)	0.10	1.41 (0.89-2.23)	0.14	1.53 (0.83-2.80)	0.17	1.22 (0.75-2.01)	0.41	1.15 (0.64-2.06)	0.64
Factor 4	3.56 (1.24-10.26)	0.02	1.05 (0.68-1.60)	0.84	0.99 (0.57-1.71)	0.99	1.20 (0.72-1.99)	0.49	0.98 (0.58-1.67)	0.95
Factor 5	1.08 (0.55-2.11)	0.82	0.95 (0.58-1.54)	0.83	1.01 (0.53-1.93)	0.97	1.01 (0.65-1.88)	0.72	0.83 (0.45-1.52)	0.54
Factor 6	1.13 (0.56-2.23)	0.73	1.07 (0.65-1.76)	0.78	1.40 (0.69-2.83)	0.35	1.21 (0.69-2.11)	0.50	1.32 (0.67-2.60)	0.42
Multivariable analysis**										
Age	1.14 (1.06-1.23)	<0.001	1.04 (1.00-1.08)	0.04	1.01 (0.95-1.07)	0.71	1.02 (0.97-1.07)	0.44	-	-
Gender (male)	-	-	-	-	-	-	2.89 (0.55-15.25)	0.21	-	-
Height	1.24 (0.93-1.64)	0.14	-	-	-	-	1.07 (0.94-1.22)	0.31	-	-
Framingham CVD risk score	1.07 (0.98-1.16)	0.10	1.02 (0.97-1.08)	0.42	1.08 (1.03-1.13)	<0.001	1.05 (1.01-1.10)	0.02	-	-
Metabolic Syndrome	-	-	2.90 (1.11-7.54)	0.03	1.41 (0.38-5.22)	0.61	-	-	-	-
HIV seropositivity	6.40 (1.30-31.45)	0.02	5.73 (2.02-16.23)	0.001	7.51 (1.73-32.71)	0.007	5.24 (1.68-16.38)	0.004	7.09 (1.50-33.59)	0.01
Factor 1	1.23 (0.41-3.78)	0.71	0.99 (0.55-1.78)	0.97	1.04 (0.48-2.25)	0.92	1.00 (0.53-1.90)	0.99	-	-
Factor 2 (VCAM, sTNFRII)	1.98 (0.90-4.35)	0.09	1.61 (0.95-2.74)	0.09	1.33 (0.65-2.69)	0.43	1.66 (0.95-2.90)	0.08	2.08 (1.08-3.99)	0.03
Factor 3 (uPAR, d-dimer, IL-6)	0.98 (0.32-2.70)	0.97	-	-	-	-	-	-	-	-
Factor 4 (MMP-2)	5.13 (1.21-21.82)	0.03	-	-	-	-	-	-	-	-

\* DSP was defined as the presence of two or more DSP signs: reduced, bilateral, symmetric, distal vibration, sharp sensation, and ankle reflexes. DNP: distal neuropathic pain; DSP: distal sensory polyneuropathy; METH: methamphetamine